1323 (1323) Fair Value & Analysis

Basic Materials · Market cap HK$153M

1 1323 1323 · HK

PriceHK$0.2180

Fair ValueHK$0.9700

Upside+345.0%

Quality55/100

Evidence: Low Range HK$0.6400 – HK$1.31

Fair value as of: Jul 2, 2026

From 7 valuation models · updated today

Share price +62.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1040 – HK$0.2250 · fair‑value band HK$0.6400 – HK$1.31 · the HK$0.2180 price screens below the HK$0.9700 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1323 (1323) currently trades at HK$0.2180, while our model-based Fair Value estimate is HK$0.9700 — implying the stock looks roughly 345.0% undervalued today. We read business quality at 55/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 1323 generated revenue of HK$282M at a net margin of -48.3%. Revenue declined 19.3% year over year. It earns a return on equity of -16.5%. Net debt stands at HK$111M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$282M

Revenue growth (YoY) -19.3%

Net margin -48.3%

Return on equity -16.5%

Free cash flow HK$117M FY2025

Operating margin -38.0%

More key figures

EPS (TTM) HK$-0.0600

EPS growth (YoY) -71.4%

Net debt HK$111M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

1323 reported revenue of HK$282M in FY2026 versus HK$804M in FY2022, a compound −23.1%/yr. Reported net income was −HK$136M in FY2026.

Revenue −23.1%/yr

FY22 HK$804M

FY23 HK$660M

FY24 HK$566M

FY25 HK$373M

FY26 HK$282M

Net income

FY22 HK$31.3M

FY23 −HK$54.8M

FY24 −HK$31.4M

FY25 −HK$92.4M

FY26 −HK$136M

Is 1323 fairly valued? → Check now

Similar stocks

6 more Building Materials stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
CRH plc CRH	$106.52	$64.08	-40%
Holcim AG HCMLY	$18.75	$9.07	-52%
Heidelberg Materials AG HEI	€185.15	€157.48	-15%
Vulcan Materials Company VMC	$281.38	$116.17	-59%
Martin Marietta Materials, Inc MLM	$609.88	$218.79	-64%
UltraTech Cement Limited ULTRACEMCO	₹10,912	₹4,589	-58%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1323 (1323) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.9700 versus a price of HK$0.2180 — about +345% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1323?

Our model-based fair value for 1323 is HK$0.9700 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2180.

What is the quality score of 1323?

1323 has a Quality Score of 55/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1323 (1323)?

1323 reported trailing-twelve-month revenue of about HK$282M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1323?

The net profit margin of 1323 is about -48.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.